A Phase II Study of Eltrombopag as a Novel Therapeutic Approach for Patients With Low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) With TET2 Mutations
This study is testing a drug called eltrombopag to see if it can help patients with specific types of blood disorders, known as MDS and CMML, produce healthier blood cells. Researchers are interested in patients who have a specific genetic change called a TET2 mutation to see if this medicine can improve their blood counts.
You may be eligible if you are at least 18 years old and have been diagnosed with low-risk MDS or CMML-0. You also need to have low blood counts for hemoglobin and certain white blood cells to join this study.
Participants will take the study drug, eltrombopag, which is designed to stimulate the bone marrow to produce more blood cells. You will need to attend regular clinic appointments so the team can monitor your blood levels and track how the treatment is working.
The study is located in Cleveland, Ohio. Please note that the study is currently suspended, so you should check with the research team for the most up-to-date information.
- 1Eltrombopag is an FDA-approved drug currently being studied as an experimental treatment for these specific blood conditions.
- 2The study focuses on patients who have a specific genetic mutation called TET2.
- 3Participants must be able to commit to the full study schedule and regular monitoring.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.